Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

PLYX Sales of Investments

Cash received from selling or redeeming investments.

Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX

Sales of Investments · Q4 FY2025 · quarter ended Dec 2025

Sales of investments outflow grows to $0

Q4 FY2025 sales of investments was $0, compared with $0 a year earlier.

Context

  • Sales of investments increased in 0 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Sales of Investments vs competitors

How PLYX compares with its peers on the latest reported figures

  • PLYX's FY2025 sales of investments of $0 is the 6th largest of the 8 companies compared; the peer median is $52.58M.
PLYX Competitors Peer median
Sales of Investments for PLYX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LYELLyell Immunopharma, Inc.LTM Mar 2026$275.21M -52.0%-3.7%887777.4%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$212M -16.7%+13.5%751.1%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$53.99M -49.3%+1.1%—
JBIOJade Biosciences, Inc.LTM Mar 2026$52.58M —-54.7%—
KLRSKalaris Therapeutics IncLTM Mar 2026$35M ———
PLYXPolaryx Therapeutics, Inc. Common StockFY2025$0 ———
CBIOCrescent Biopharma, Inc.LTM Mar 2026$0 ——0.0%
PTHSPelthos Therapeutics Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding PLYX) $52.58M-49.3%-1.3%375.6%

Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Intrinsic Alpha fair value

Locked

Current Price

$1.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.